Dr. Pasi Jänne led a study that showed a drug shrank lung tumors in 61 percent of patients whose cancers had developed the T790-M resistance mutation. He also commented on personalized medicine for cancer patients.
Tags: LungCancer, TargetedTherapy
Dr. Philip Kantoff and Dr. Lauren Harshman led a study that found hormone-sensitive prostate cancer patients who started on cholesterol-lowering statin drugs at initiation of androgen-deprivation therapy experienced a longer time to disease progression.
Fifty-three Dana-Farber nurses were recognized by patients
in the Boston Globe as part of the annual "Salute to Nurses"
supplement in celebration of National Nurses Week.
Dr. Pasi Janne led a study showing a new targeted drug as a promising treatment for advanced lung cancers.
Dr. Joanne Wolfe led a study that examined symptom distress
in children living with advanced cancer, and found that a majority experience
high symptom distress.
Dr. Judy Garber discussed breast cancer among men and the lack of awareness despite a surge in news surrounding the BRCA gene.
Dana-Farber nutritionist Stacy Kennedy, MPH, discussed the importance of maintaining good nutrition for cancer patients.
Dr. Mehra Golshan led a study that shows many patients are
opting for a mastectomy despite the high success rates a lumpectomy can offer.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: